{{Chembox
| ImageFile = LF 22-0542.svg
| ImageSize = 200px
| ImageAlt =
| IUPACName = ''N''-<nowiki>[[</nowiki>4-(4,5-Dihydro-1''H''-imidazol-2-yl)phenyl]methyl]-2-[2-<nowiki>[[</nowiki>(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-''N''-methylacetamide
| OtherNames =
|Section1={{Chembox Identifiers
| CASNo = 633698-99-4
| CASNo_Ref = {{cascite|correct|}}
|  PubChem = 11953367
|  ChemSpiderID = 10127675
|  SMILES = Cc1cc(cc(c1S(=O)(=O)N(C)CCOCC(=O)N(C)Cc2ccc(cc2)C3=NCCN3)C)OC
|  InChI = 1/C25H34N4O5S/c1-18-14-22(33-5)15-19(2)24(18)35(31,32)29(4)12-13-34-17-23(30)28(3)16-20-6-8-21(9-7-20)25-26-10-11-27-25/h6-9,14-15H,10-13,16-17H2,1-5H3,(H,26,27)
|  InChIKey = AMTQCENHQIDBHQ-UHFFFAOYAH
|  StdInChI = 1S/C25H34N4O5S/c1-18-14-22(33-5)15-19(2)24(18)35(31,32)29(4)12-13-34-17-23(30)28(3)16-20-6-8-21(9-7-20)25-26-10-11-27-25/h6-9,14-15H,10-13,16-17H2,1-5H3,(H,26,27)
|  StdInChIKey = AMTQCENHQIDBHQ-UHFFFAOYSA-N}}
|Section2={{Chembox Properties
| C=25 | H=34 | N=4 | O=5 | S=1
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility = }}
|Section3={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt = }}
}}

'''Safotibant''' (INN<ref>{{cite web|title=Safotibant INN|url=https://mednet-communities.net/inn/db/ViewINN.aspx?i=9479|website=Mednet|accessdate=31 March 2016}}</ref>) also known by the research code LF22-0542 is a non-peptide [[Bradykinin receptor B1|bradykinin B<sub>1</sub>]] [[antagonist]]. It displayed binding Ki values of 0.35 and 6.5 nM at cloned human and mouse B<sub>1</sub> receptors, respectively, while having no affinity for either human, mouse, or rat B<sub>2</sub> receptors at concentrations up to 10 μM. This means that LF22-0542 is at least 4000 times selective for the B<sub>1</sub> receptor over the [[Bradykinin receptor B2|B<sub>2</sub> receptor]]. Systemic administration of LF22-0542 inhibited acute pain induced by [[acetic acid]], [[formalin]], and a hot plate. It also reversed acute inflammatory pain induced by [[carrageenan]], and persistent inflammatory pain induced by [[Freund's adjuvant|CFA]]. In a [[neuropathic pain]] model, LF22-0542 reversed the thermal [[hyperalgesia]], but not the mechanical hyperalgesia.<ref name=Porreca>{{cite journal|last=Porreca|first=Frank|title=Antinociceptive Pharmacology of N-<nowiki>[[</nowiki>4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-<nowiki>[[</nowiki>(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy]-N-methylacetamide, Fumarate (LF22-0542), a Novel Nonpeptidic Bradykinin B1 Receptor Antagonist|journal=The Journal of Pharmacology and Experimental Therapeutics|date=July 2006|volume=318|issue=1|pages=195–205|doi=10.1124/jpet.105.098368|pmid=16565167}}</ref>

==References==
{{Reflist}}


{{Peptidergics}}

[[Category:Analgesics]]
[[Category:Anti-inflammatory agents]]
[[Category:Sulfonamides]]
[[Category:Imidazolines]]